Cancer Center News

Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

CHOP researchers found that a series of “liquid biopsies” could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma.

Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.

CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.

Presenting Sponsor Citadel Credit Union Doubled Pledge and Renewed its Partnership for Annual Event Aimed at Conquering Childhood Cancer.

A new study by a multi-institutional group of pediatric cancer researchers, including those at CHOP, has characterized the genomic landscape for acute lymphoblastic leukemia.

A leading study site for nearly a decade, CHOP will be part of a network of treatment centers in the country offering the therapy to patients who require regular blood transfusions.

CHOP has helped launch NCI-backed “Molecular Targets Platform” to streamline and catalyze drug development by harmonizing data about pediatric cancer targets and pathways.

CHOP played an instrumental role in leading one of two clinical trials that led to the approval of Xalkori® for unresectable, recurrent, or refractory ALK-positive IMT.